drugset / Trial / NCT00836082

A Multiple Dose Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04457845 in Healthy Volunteers

NCT00836082

Phase 1 Completed 41 enrolled Pfizer
RandomizedParallel-groupDouble-blind

Summary

To determine if PF-04457845 at doses of 0.5mg, 1mg, 4mg, and 8 mg given once daily for 14 days will be safe and well tolerated in healthy volunteers. To determine the effect on food on PF-04457845 pharmacokinetics and safety following administration of single doses of 4mg and 8mg.

Timeline

Start
2009-02
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject REDAFAMDASTAT Small molecule 0.5 mg Oral
Subject REDAFAMDASTAT Small molecule 1 mg Oral
Subject REDAFAMDASTAT Small molecule 4 mg Oral
Subject REDAFAMDASTAT Small molecule 8 mg Oral

Indications